264 related articles for article (PubMed ID: 7761575)
1. p53 alterations in plutonium-induced F344 rat lung tumors.
Kelly G; Stegelmeier BL; Hahn FF
Radiat Res; 1995 Jun; 142(3):263-9. PubMed ID: 7761575
[TBL] [Abstract][Full Text] [Related]
2. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
3. p53, erbB-2 and K-ras gene alterations are rare in spontaneous and plutonium-239-induced canine lung neoplasia.
Tierney LA; Hahn FF; Lechner JF
Radiat Res; 1996 Feb; 145(2):181-7. PubMed ID: 8606928
[TBL] [Abstract][Full Text] [Related]
4. Mutations in Tp53 gene sequences from lung tumors in rats that inhaled plutonium dioxide.
Yamada Y; Oghiso Y
Radiat Res; 1999 Dec; 152(6 Suppl):S107-9. PubMed ID: 10564948
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
[TBL] [Abstract][Full Text] [Related]
6. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
7. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
8. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
9. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
10. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis.
Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H
Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particles.
Andersson M; Jönsson M; Nielsen LL; Vyberg M; Visfeldt J; Storm HH; Wallin H
Cancer Epidemiol Biomarkers Prev; 1995; 4(7):765-70. PubMed ID: 8672994
[TBL] [Abstract][Full Text] [Related]
12. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
[TBL] [Abstract][Full Text] [Related]
13. p53 mutations in lung cancer following radiation therapy for Hodgkin's disease.
De Benedetti VM; Travis LB; Welsh JA; van Leeuwen FE; Stovall M; Clarke EA; Boice JD; Bennett WP
Cancer Epidemiol Biomarkers Prev; 1996 Feb; 5(2):93-8. PubMed ID: 8850268
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
15. p53 alterations in chemically induced hamster cheek-pouch lesions.
Gimenez-Conti IB; LaBate M; Liu F; Osterndorff E
Mol Carcinog; 1996 Aug; 16(4):197-202. PubMed ID: 8784462
[TBL] [Abstract][Full Text] [Related]
16. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
17. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung.
Kishimoto Y; Murakami Y; Shiraishi M; Hayashi K; Sekiya T
Cancer Res; 1992 Sep; 52(17):4799-804. PubMed ID: 1324794
[TBL] [Abstract][Full Text] [Related]
18. p53 mutational spectrum of esophageal carcinomas from five different geographical locales in China.
Lung ML; Chan WC; Zong YS; Tang CM; Fok CL; Wong KT; Chan LK; Lau KW
Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):277-84. PubMed ID: 8722219
[TBL] [Abstract][Full Text] [Related]
19. Analysis of radon-associated squamous cell carcinomas of the lung for a p53 gene hotspot mutation.
Yang Q; Wesch H; Mueller KM; Bartsch H; Wegener K; Hollstein M
Br J Cancer; 2000 Feb; 82(4):763-6. PubMed ID: 10732742
[TBL] [Abstract][Full Text] [Related]
20. Low incidence of point mutations detected in the p53 tumor suppressor gene from chemically induced rat renal mesenchymal tumors.
Weghorst CM; Dragnev KH; Buzard GS; Thorne KL; Vandeborne GF; Vincent KA; Rice JM
Cancer Res; 1994 Jan; 54(1):215-9. PubMed ID: 8261441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
